Intratumoral heterogeneity, treatment response, and survival outcome of ER-positive HER2-positive breast cancer.

ABSTRACT:

Background

ER+HER2+ breast cancer requires most types of systemic therapies perioperatively. However, treatment resistance is often experienced. The current study investigated the predictive and prognostic value of intratumoral heterogeneity and conventional clinicopathological factors in patients with ER+HER2+ breast cancer.

Methods

This research included two patient cohorts with ER+HER2+ breast cancer. Cohort A included patients who underwent surgery without neoadjuvant chemotherapy (NAC). Cohort B comprised patients who received NAC followed by surgery. Intratumoral heterogeneity was assessed via ER and HER2 double staining, and the number of cells stained with different patterns of ER and HER2 was counted.

Results

In total, 11 of 92 tumors in cohort A and four of

SUBMITTER: Teruya N 

PROVIDER: S-EPMC10225233 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature